Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

NCT03787498 is registered in ClinicalTrials.gov with Opna Bio LLC as lead sponsor.

NCT NCT03787498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03787498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Lead sponsor
Opna Bio LLC
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2019
Completion date
June 30, 2021
Enrollment
22 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk myelodysplastic syndrome (mds), refractory acute myeloid leukemia (aml), relapsed acute myeloid leukemia (aml)